The decision by the US National Institutes of Health to streamline its regulation of gene therapy clinical trials is a recognition that the category has entered the treatment mainstream.
Under a proposal announced Aug. 16, NIH's Recombinant DNA Advisory Committee (RAC) would stop receiving and reviewing initial trial protocols,...